Aliases & Classifications for Malignant Glioma

Aliases & Descriptions for Malignant Glioma:

Name: Malignant Glioma 38 52 69

Classifications:



Summaries for Malignant Glioma

MalaCards based summary : Malignant Glioma is related to astrocytoma and glioma. An important gene associated with Malignant Glioma is MGMT (O-6-Methylguanine-DNA Methyltransferase), and among its related pathways/superpathways are Innate Immune System and Apoptotic Pathways in Synovial Fibroblasts. The drugs Dacarbazine and Temozolomide have been mentioned in the context of this disorder. Affiliated tissues include brain, endothelial and bone, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and homeostasis/metabolism

Related Diseases for Malignant Glioma

Diseases in the Glioma family:

Malignant Glioma

Diseases related to Malignant Glioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 171)
id Related Disease Score Top Affiliating Genes
1 astrocytoma 11.2
2 glioma 11.1
3 malignant ependymoma 10.8
4 mismatch repair cancer syndrome 10.8
5 meningioma, familial 10.8
6 facio skeletal genital syndrome rippberger type 10.3 MMP2 MMP9
7 thymus adenocarcinoma 10.3 EGFR MMP2 MMP9
8 bronchopulmonary dysplasia 10.3 GFAP MMP9
9 liver fibrosarcoma 10.3 GFAP TP53
10 clear cell adenofibroma 10.3 CDKN2A TP53
11 wolffian adnexal neoplasm 10.3 EGFR TP53
12 senile atrophy of choroid 10.3 MMP2 MMP9 VEGFA
13 striated muscle rhabdoid tumor 10.3 CDKN2A MMP2 MMP9
14 chronic monocytic leukemia 10.3 CDKN2A EGFR TP53
15 his bundle tachycardia 10.3 BCL2 EGFR TP53
16 paternal uniparental disomy of chromosome 1 10.3 EGFR GFAP TP53
17 adenoid squamous cell carcinoma 10.3 CDKN2A MMP2 MMP9
18 thymus squamous cell carcinoma 10.3 CDKN2A EGFR TP53
19 adult neuronal ceroid lipofuscinosis 10.3 MMP2 MMP9 VEGFA
20 secondary hyperparathyroidism of renal origin 10.3 CDKN2A EGFR TP53
21 endometrial squamous cell carcinoma 10.3 CDKN2A MGMT TP53
22 statin toxicity 10.3 BCL2 MMP9 TP53
23 pyloric antrum cancer 10.2 BCL2 TP53 VEGFA
24 lacrimal gland adenoid cystic carcinoma 10.2 CDKN2A TP53
25 onychocytic matricoma 10.2 MMP2 MMP9 VEGFA
26 primary tubular proximal acidosis 10.2 BCL2 CDKN2A MGMT
27 cervical adenoid cystic carcinoma 10.2 GFAP TP53
28 allergic contact dermatitis 10.2 CDKN2A EGFR TP53
29 urethral verrucous carcinoma 10.2 CDKN2A PTEN TP53
30 immunodeficiency due to a late component of complement deficiency 10.2 EGFR TP53 VEGFA
31 brain stem astrocytic neoplasm 10.2 GFAP MGMT TP53
32 amyloid tumor 10.2 GFAP MGMT TP53
33 estrogen-receptor positive breast cancer 10.2 CDKN2A EGFR TP53
34 tumor of exocrine pancreas 10.2 CDKN2A EGFR VEGFA
35 pityriasis rosea 10.2 CDKN2A EGFR TP53
36 cutaneous adenocystic carcinoma 10.2 GFAP MGMT TP53
37 placental site trophoblastic tumor 10.2 CDKN2A TP53 VEGFA
38 pyomyositis 10.2 CDKN2A EGFR TP53
39 plasmodium ovale malaria 10.2 CDKN2A GFAP TP53
40 pacinian tumor 10.2 CDKN2A GFAP TP53
41 nodular cutaneous amyloidosis 10.2 CDKN2A MMP2 MMP9 TP53
42 ophn1 syndrome 10.2 GFAP MGMT
43 maxillary sinus cholesteatoma 10.2 CDKN2A MMP2 MMP9 TP53
44 traumatic brain injury 10.2 CDKN2A MMP2 MMP9 TP53
45 lattice corneal dystrophy 10.2 CDKN2A MMP2 MMP9 TP53
46 endotheliitis 10.2
47 spastic paraplegia 1 10.2 BCL2 EGFR TP53 VEGFA
48 metagonimiasis 10.2 MMP2 TP53 VEGFA
49 pituitary infarct 10.2 MMP9 PTEN VEGFA
50 connective tissue benign neoplasm 10.2 CDKN2A EGFR TP53

Graphical network of the top 20 diseases related to Malignant Glioma:



Diseases related to Malignant Glioma

Symptoms & Phenotypes for Malignant Glioma

GenomeRNAi Phenotypes related to Malignant Glioma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.92 PTK2 TNFRSF10B TNFSF10 TP53 BCL2 CASP8
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.92 TNFRSF10B TNFSF10 TP53 BCL2 CASP8 CDKN2A
3 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.43 MGMT PTK2 TNFRSF10B TP53 BCL2 CASP8

MGI Mouse Phenotypes related to Malignant Glioma:

44 (show all 20)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.48 BCL2 CASP8 CDKN2A CFLAR DMBT1 EGFR
2 immune system MP:0005387 10.44 BCL2 CASP8 CDKN2A CFLAR DMBT1 EGF
3 cardiovascular system MP:0005385 10.4 BCL2 CASP8 CDKN2A CFLAR EGFR GFAP
4 mortality/aging MP:0010768 10.39 PTEN PTK2 TNFSF10 TP53 VEGFA BCL2
5 hematopoietic system MP:0005397 10.38 BCL2 CASP8 CDKN2A CFLAR EGFR IL13RA1
6 endocrine/exocrine gland MP:0005379 10.37 BCL2 CASP8 CDKN2A CFLAR EGF EGFR
7 cellular MP:0005384 10.36 CASP8 CDKN2A CFLAR DMBT1 EGFR GFAP
8 growth/size/body region MP:0005378 10.36 MMP2 MMP9 PTEN PTK2 TP53 VEGFA
9 digestive/alimentary MP:0005381 10.32 BCL2 CDKN2A DMBT1 EGF EGFR GFAP
10 embryo MP:0005380 10.22 CASP8 CDKN2A CFLAR DMBT1 EGFR PTEN
11 neoplasm MP:0002006 10.22 BCL2 CASP8 CDKN2A DMBT1 EGFR MGMT
12 muscle MP:0005369 10.21 PTK2 TP53 VEGFA BCL2 CASP8 CDKN2A
13 integument MP:0010771 10.19 EGFR MMP9 PTEN PTK2 TP53 VEGFA
14 nervous system MP:0003631 10.11 BCL2 CASP8 CDKN2A EGFR GFAP MMP2
15 liver/biliary system MP:0005370 10.08 CASP8 CDKN2A EGFR PTEN PTK2 TNFSF10
16 renal/urinary system MP:0005367 9.86 BCL2 CASP8 DMBT1 EGFR MMP9 PTEN
17 reproductive system MP:0005389 9.81 BCL2 CDKN2A EGF EGFR MMP9 PTEN
18 respiratory system MP:0005388 9.77 VEGFA BCL2 CASP8 CDKN2A EGFR IL13RA1
19 pigmentation MP:0001186 9.72 BCL2 CDKN2A EGFR PTEN TP53
20 vision/eye MP:0005391 9.32 BCL2 CDKN2A EGF EGFR GFAP MMP2

Drugs & Therapeutics for Malignant Glioma

Drugs for Malignant Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 395)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 4342-03-4 5351166
2
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 85622-93-1 5394
3 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
4 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1
5
Carmustine Approved Phase 3,Phase 2,Phase 1 154-93-8 2578
6
Lomustine Approved Phase 3,Phase 2,Phase 1 13010-47-4 3950
7
Procarbazine Approved Phase 3,Phase 2 671-16-9 4915
8
Trioxsalen Approved Phase 3,Phase 2,Phase 1 3902-71-4 5585
9
Carboplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 498142 38904
10
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
11
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
12
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
13
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
14
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
15
Thiotepa Approved Phase 3,Phase 2,Phase 1 52-24-4 5453
16
Vincristine Approved, Investigational Phase 3,Phase 1 2068-78-2, 57-22-7 5978
17
Aminolevulinic acid Approved Phase 3,Phase 2,Phase 1 106-60-5 137
18
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 1 216974-75-3
19
Octreotide Approved, Investigational Phase 2, Phase 3,Phase 1 83150-76-9 383414 6400441
20
Somatostatin Approved Phase 2, Phase 3,Phase 1 38916-34-6, 51110-01-1 53481605
21
Dalteparin Approved Phase 3 9041-08-1
22
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
23
chloroquine Approved, Vet_approved Phase 3 54-05-7 2719
24
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
25
Benzocaine Approved Phase 3,Phase 2 1994-09-7, 94-09-7 2337
26
Levoleucovorin Approved Phase 3 68538-85-2
27 Sodium thiosulfate Approved Phase 3,Phase 2,Phase 1
28
Vorinostat Approved, Investigational Phase 2, Phase 3,Phase 1 149647-78-9 5311
29
Isotretinoin Approved Phase 3,Phase 2,Phase 1 4759-48-2 5538 5282379
30
nivolumab Approved Phase 3,Phase 2,Phase 1 946414-94-4
31
Metformin Approved Phase 3 657-24-9 14219 4091
32
Dopamine Approved Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
33
Meloxicam Approved, Vet_approved Phase 2, Phase 3 71125-38-7 5281106 54677470
34
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
35
Norepinephrine Approved Phase 3 51-41-2 439260
36
Cyproheptadine Approved Phase 3 129-03-3 2913
37
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
38
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
39
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
40 tannic acid Approved, Nutraceutical Phase 3,Phase 2
41
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 5538
42
Vitamin C Approved, Nutraceutical Phase 3,Phase 1,Phase 2 50-81-7 5785 54670067
43 Dermatologic Agents Phase 3,Phase 2,Phase 1
44 Dihematoporphyrin Ether Phase 3,Phase 2,Phase 1
45 Ether Phase 3,Phase 2,Phase 1
46 Photosensitizing Agents Phase 3,Phase 2,Phase 1
47 Antimetabolites Phase 3,Phase 2,Phase 1
48 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
49 Antimitotic Agents Phase 3,Phase 1,Phase 2
50 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 576)
id Name Status NCT ID Phase
1 Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas Not yet recruiting NCT02496988 Phase 4
2 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3
3 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3
4 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3
5 Study of NPC-07 for Fluorescence-guided Resection of Malignant Gliomas Completed NCT01167322 Phase 3
6 Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT Completed NCT01460706 Phase 2, Phase 3
7 Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid Completed NCT00241670 Phase 3
8 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3
9 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3
10 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3
11 Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients Completed NCT00135876 Phase 3
12 Chloroquine for Treatment of Glioblastoma Multiforme Completed NCT00224978 Phase 3
13 The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme Completed NCT00076986 Phase 3
14 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3
15 Radiation Therapy in Treating Patients With Brain Cancer Completed NCT00002620 Phase 3
16 Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly Completed NCT01502241 Phase 3
17 S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma Completed NCT00017147 Phase 3
18 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
19 Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Completed NCT00916409 Phase 3
20 Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma Completed NCT00336024 Phase 3
21 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3
22 Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over Recruiting NCT02892708 Phase 3
23 A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment Recruiting NCT02629757 Phase 3
24 3D Ultra Sound for Resection of Brain Tumors Recruiting NCT02150564 Phase 3
25 iMRI Guided Resection in Cerebral Glioma Surgery Recruiting NCT01479686 Phase 3
26 Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients Recruiting NCT02796261 Phase 3
27 An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) Recruiting NCT02617589 Phase 3
28 Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma Recruiting NCT01096368 Phase 3
29 Placebo Controlled Double Blind Crossover Trial of Metformin for Brain Repair in Children With Cranial-Spinal Radiation for Medulloblastoma Recruiting NCT02040376 Phase 3
30 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Active, not recruiting NCT01236560 Phase 2, Phase 3
31 MEDICO-ECONOMIC EVALUATION OF SURGERY GUIDED BY FLUORESCENCE FOR THE OPTIMIZATION OF RESECTION OF GLIOBLASTOMAS Active, not recruiting NCT01811121 Phase 3
32 Proteome-based Personalized Immunotherapy of Glioblastoma Enrolling by invitation NCT01759810 Phase 2, Phase 3
33 The Effect of Duloxetine on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients Terminated NCT02443194 Phase 3
34 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
35 Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3
36 XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema Withdrawn NCT00226668 Phase 3
37 Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma Unknown status NCT01144988 Phase 2
38 Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas Unknown status NCT01670890 Phase 2
39 A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma Unknown status NCT00683761 Phase 1, Phase 2
40 Radiation With Concomitant and Then Sequential Temozolomide in Malignant Glioma Unknown status NCT00283543 Phase 2
41 Dendritic Cell (DC) Activated Cytokine-induced Killer Cell (DCIK) Combined With DC Treatment for Glioma Unknown status NCT01235845 Phase 1, Phase 2
42 Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma Unknown status NCT00045110 Phase 1, Phase 2
43 Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma Unknown status NCT00004204 Phase 2
44 Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma Unknown status NCT00047281 Phase 2
45 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2
46 Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas Unknown status NCT00492687 Phase 2
47 Cisplatin and Temozolomide in Treating Young Patients With Malignant Glioma Unknown status NCT00360945 Phase 2
48 A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2
49 Safety Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain Unknown status NCT01116661 Phase 2
50 Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme Unknown status NCT00906516 Phase 2

Search NIH Clinical Center for Malignant Glioma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Malignant Glioma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Malignant Glioma:
ALD-451, bone marrow-derived cells for malignant glioma
Embryonic/Adult Cultured Cells Related to Malignant Glioma:
Bone marrow-derived ALDH+ cells (ALD) PMIDs: 10430905

Genetic Tests for Malignant Glioma

Anatomical Context for Malignant Glioma

MalaCards organs/tissues related to Malignant Glioma:

39
Brain, Endothelial, Bone, T Cells, Monocytes, Bone Marrow, Prostate

Publications for Malignant Glioma

Articles related to Malignant Glioma:

(show top 50) (show all 1167)
id Title Authors Year
1
DNA methylation-mediated caspase-8 downregulation is associated with anti-apoptotic activity and human malignant glioma grade. ( 28204824 )
2017
2
The regulator of calcineurin 1 (RCAN1) inhibits nuclear factor kappaB signaling pathway and suppresses human malignant glioma cells growth. ( 28061453 )
2017
3
Hypoxia-induced production of peptidylarginine deiminases and citrullinated proteins in malignant glioma cells. ( 27818200 )
2017
4
Anti-GITR therapy promotes immunity against malignant glioma in a murine model. ( 27734112 )
2016
5
Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma. ( 27826680 )
2016
6
MiR-129 triggers autophagic flux by regulating a novel Notch-1/ E2F7/Beclin-1 axis to impair the viability of human malignant glioma cells. ( 26824182 )
2016
7
Integrin I+VI^3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair. ( 27487141 )
2016
8
An Overview of Alternating Electric Fields Therapy (NovoTTF Therapy) for the Treatment of Malignant Glioma. ( 26739692 )
2016
9
Malignant glioma in vitro models: On the utilization of stem-like cells and the recapitulation of molecular subtypes. ( 27528360 )
2016
10
Down-regulation of long non-coding RNA FOXD3 antisense RNA 1 (FOXD3-AS1) inhibits cell proliferation, migration, and invasion in malignant glioma cells. ( 27829996 )
2016
11
A novel manganese complex selectively induces malignant glioma cell death by targeting mitochondria. ( 27432745 )
2016
12
Focused Ultrasound Enhances Central Nervous System Delivery of Bevacizumab for Malignant Glioma Treatment. ( 27192459 )
2016
13
Malignant Glioma with Neuronal Marker Expression : A Clinicopathological Study of 18 Cases. ( 26885285 )
2016
14
Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma. ( 27599828 )
2016
15
Quantitative analysis of brain edema in patients with malignant glioma treated with BCNU wafers. ( 27452129 )
2016
16
c-Fos over-expression promotes radioresistance and predicts poor prognosis in malignant glioma. ( 27602752 )
2016
17
NKG2D- and T-cell receptor-dependent lysis of malignant glioma cell lines by human I^I' T cells: Modulation by temozolomide and A disintegrin and metalloproteases 10 and 17 inhibitors. ( 27141377 )
2016
18
Regulatory landscape and clinical implication of MBD3 in human malignant glioma. ( 27835581 )
2016
19
Malignant glioma with primitive neuroectodermal tumor-like component (MG-PNET): novel microarray findings in a pediatric patient. ( 27781423 )
2016
20
Focused Ultrasound Enhances Central Nervous System Delivery of Bevacizumab for Malignant Glioma Treatment. ( 27861405 )
2016
21
Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis. ( 27877052 )
2016
22
Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma. ( 27188199 )
2016
23
Olig2-Dependent Reciprocal Shift in PDGF and EGF Receptor Signaling Regulates Tumor Phenotype and Mitotic Growth in Malignant Glioma. ( 27165742 )
2016
24
Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma. ( 26873960 )
2016
25
Advanced interstitial chemotherapy combined with targeted treatment of malignant glioma in rats by using drug-loaded nanofibrous membranes. ( 27494894 )
2016
26
Exploring the activity of a polyazine bridged Ru(ii)-Pt(ii) supramolecule in F98 rat malignant glioma cells. ( 27901157 )
2016
27
Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas. ( 26757925 )
2016
28
Inhibition of PTTG1 expression by microRNA suppresses proliferation and induces apoptosis of malignant glioma cells. ( 27900021 )
2016
29
Radiotherapy induces an immediate inflammatory reaction in malignant glioma: a clinical microdialysis study. ( 27664151 )
2016
30
Simultaneous Administration of Statins and Pioglitazone Limits Tumor Growth in a Rat Model of Malignant Glioma. ( 27919957 )
2016
31
Perfusion MRI as the predictive/prognostic and pharmacodynamic biomarkers in recurrent malignant glioma treated with bevacizumab: a systematic review and a time-to-event meta-analysis. ( 27108275 )
2016
32
High expression of UBE2C is associated with the aggressive progression and poor outcome of malignant glioma. ( 26998166 )
2016
33
Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. ( 27576783 )
2016
34
The potential roles of dopamine in malignant glioma. ( 27995487 )
2016
35
Emerging Approaches for Targeting Metabolic Vulnerabilities in Malignant Glioma. ( 26759318 )
2016
36
Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: phase I study. ( 26945581 )
2016
37
The multidrug-resistance transporter Abcc3 protects NK cells from chemotherapy in a murine model of malignant glioma. ( 27467914 )
2016
38
TRPM7 channel inhibition mediates midazolam-induced proliferation loss in human malignant glioma. ( 27629139 )
2016
39
Fluorescence-Guided Resection of Malignant Glioma with 5-ALA. ( 27429612 )
2016
40
Endothelin B receptor expression in malignant gliomas: the perivascular immune escape mechanism of gliomas. ( 26645886 )
2016
41
Concurrent Chemotherapy of Malignant Glioma in Rats by Using Multidrug-Loaded Biodegradable Nanofibrous Membranes. ( 27471070 )
2016
42
Akt and I^-catenin contribute to TMZ resistance and EMT of MGMT negative malignant glioma cell line. ( 27423571 )
2016
43
Improving vaccine efficacy against malignant glioma. ( 27622066 )
2016
44
Identification of two distinct mesenchymal stromal cell populations in human malignant glioma. ( 27757723 )
2016
45
Lesion momentum as explanation for preoperative neurocognitive function in patients with malignant glioma. ( 27880642 )
2016
46
Targeting immune checkpoints in malignant glioma. ( 27756892 )
2016
47
Combination of lentivirus-mediated silencing of PPM1D and temozolomide chemotherapy eradicates malignant glioma through cell apoptosis and cell cycle arrest. ( 27633132 )
2016
48
MicroRNA-203 Modulates the Radiation Sensitivity of Human Malignant Glioma Cells. ( 26678661 )
2016
49
Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations. ( 26989128 )
2016
50
WTAP Expression Predicts Poor Prognosis in Malignant Glioma Patients. ( 27370540 )
2016

Variations for Malignant Glioma

Copy number variations for Malignant Glioma from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 74684 13 110300000 115169878 Deletion Malignant glioma
2 75161 13 16300000 19500000 Deletion Malignant glioma
3 75381 13 19500000 32200000 Deletion Malignant glioma
4 77097 13 40100000 45200000 Deletion Malignant glioma
5 178248 3 69788586 70017488 Amplification MITF Malignant glioma

Expression for Malignant Glioma

Search GEO for disease gene expression data for Malignant Glioma.

Pathways for Malignant Glioma

Pathways related to Malignant Glioma according to GeneCards Suite gene sharing:

(show top 50) (show all 72)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.1 BCL2 CASP8 EGF EGFR IL13RA1 IL13RA2
2
Show member pathways
13.89 BCL2 CASP8 CDKN2A CFLAR EGF EGFR
3
Show member pathways
13.75 BCL2 CASP8 CDKN2A CFLAR EGF EGFR
4
Show member pathways
13.73 BCL2 CASP8 CFLAR EGF EGFR IL13RA1
5
Show member pathways
13.6 BCL2 EGF EGFR IL13RA1 IL13RA2 TNFRSF10B
6
Show member pathways
13.46 BCL2 EGF EGFR IL13RA1 IL13RA2 PTEN
7
Show member pathways
13.41 BCL2 EGF EGFR IL13RA1 IL13RA2 MMP2
8
Show member pathways
13.34 BCL2 CASP8 EGF EGFR IL13RA1 IL13RA2
9
Show member pathways
12.97 BCL2 CASP8 CFLAR MMP9 PTEN TP53
10
Show member pathways
12.96 BCL2 EGF EGFR PTEN PTK2 VEGFA
11
Show member pathways
12.95 BCL2 CASP8 CFLAR MMP9 TNFRSF10B TNFSF10
12
Show member pathways
12.93 BCL2 CDKN2A EGF EGFR MMP2 MMP9
13
Show member pathways
12.9 BCL2 CASP8 CDKN2A CFLAR TNFRSF10B TNFSF10
14
Show member pathways
12.83 BCL2 PTEN PTK2 TP53 VEGFA
15
Show member pathways
12.67 BCL2 CASP8 TNFRSF10B TNFSF10 VEGFA
16
Show member pathways
12.65 BCL2 EGFR MMP2 PTK2 TP53
17 12.64 BCL2 EGF EGFR PTEN PTK2 TP53
18
Show member pathways
12.64 CASP8 CFLAR EGFR MMP2 MMP9 PTEN
19
Show member pathways
12.59 CASP8 EGF EGFR MMP2 MMP9 PTK2
20 12.54 BCL2 CDKN2A EGFR MMP9 PTEN TP53
21
Show member pathways
12.51 BCL2 CASP8 EGFR PTK2 TP53
22
Show member pathways
12.44 CASP8 CDKN2A PTEN TNFRSF10B TP53
23
Show member pathways
12.42 BCL2 EGF EGFR PTEN PTK2 TP53
24
Show member pathways
12.41 EGF EGFR PTK2 VEGFA
25
Show member pathways
12.37 CASP8 CFLAR TNFRSF10B TNFSF10
26 12.37 EGFR MMP2 MMP9 PTK2 TP53 VEGFA
27
Show member pathways
12.36 EGF EGFR PTK2 TP53
28
Show member pathways
12.34 CASP8 CFLAR TNFRSF10B TNFSF10
29 12.33 BCL2 CASP8 CFLAR TNFRSF10B TNFSF10
30
Show member pathways
12.32 BCL2 CASP8 PTEN TNFRSF10B TNFSF10 TP53
31
Show member pathways
12.28 EGFR PTEN PTK2 VEGFA
32
Show member pathways
12.26 BCL2 GFAP IL13RA1 IL13RA2
33 12.24 EGF EGFR PTEN PTK2
34 12.23 EGF EGFR MMP2 MMP9 TP53 VEGFA
35 12.2 BCL2 IL13RA1 PTEN PTK2 TP53
36
Show member pathways
12.18 CDKN2A EGF EGFR TP53 VEGFA
37
Show member pathways
12.17 EGF EGFR MMP2 PTEN
38 12.16 BCL2 CDKN2A MGMT PTEN TP53
39 12.16 BCL2 CASP8 EGFR PTEN TP53 VEGFA
40
Show member pathways
12.14 EGF EGFR PTEN TNFSF10
41 12.1 BCL2 MMP2 MMP9 PTK2 TP53 VEGFA
42
Show member pathways
12.09 CASP8 EGFR PTK2 TP53
43 12.08 EGFR GFAP MMP9 TP53
44 12.05 BCL2 CDKN2A PTEN TP53
45 12.05 BCL2 EGFR MMP2 PTEN TNFRSF10B TP53
46 12.01 BCL2 CDKN2A PTEN TP53
47
Show member pathways
11.99 CASP8 EGF EGFR PTK2
48 11.98 BCL2 EGF EGFR VEGFA
49 11.96 CDKN2A EGF EGFR MGMT PTEN TP53
50 11.96 BCL2 CASP8 CDKN2A EGF EGFR MMP2

GO Terms for Malignant Glioma

Cellular components related to Malignant Glioma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 DMBT1 EGF EGFR IL13RA2 MMP2 MMP9
2 death-inducing signaling complex GO:0031264 9.26 CASP8 CFLAR
3 ripoptosome GO:0097342 9.16 CASP8 CFLAR
4 CD95 death-inducing signaling complex GO:0031265 8.62 CASP8 CFLAR

Biological processes related to Malignant Glioma according to GeneCards Suite gene sharing:

(show all 31)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.97 CDKN2A MMP9 PTEN TNFSF10 TP53
2 cell surface receptor signaling pathway GO:0007166 9.95 CASP8 EGFR IL13RA1 TNFRSF10B TNFSF10
3 apoptotic process GO:0006915 9.92 BCL2 CASP8 CDKN2A CFLAR PTEN TNFRSF10B
4 positive regulation of cell migration GO:0030335 9.91 EGFR MMP9 PTK2 VEGFA
5 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.9 CASP8 CFLAR TNFRSF10B TNFSF10
6 positive regulation of protein phosphorylation GO:0001934 9.89 EGFR MMP9 PTK2 VEGFA
7 regulation of apoptotic process GO:0042981 9.89 BCL2 CASP8 CFLAR TNFRSF10B TP53
8 angiogenesis GO:0001525 9.88 EGF MMP2 PTEN PTK2 VEGFA
9 phosphatidylinositol-mediated signaling GO:0048015 9.83 EGF EGFR PTEN TP53
10 cellular response to mechanical stimulus GO:0071260 9.81 CASP8 EGFR TNFRSF10B
11 regulation of protein stability GO:0031647 9.8 BCL2 CDKN2A PTEN
12 positive regulation of MAP kinase activity GO:0043406 9.79 EGF EGFR VEGFA
13 epidermal growth factor receptor signaling pathway GO:0007173 9.79 EGF EGFR PTK2
14 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.76 CASP8 CDKN2A TNFRSF10B TNFSF10
15 execution phase of apoptosis GO:0097194 9.74 CASP8 CFLAR PTK2
16 positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:1900740 9.71 BCL2 CASP8 TP53
17 positive regulation of release of cytochrome c from mitochondria GO:0090200 9.69 MMP9 TNFSF10 TP53
18 regulation of necroptotic process GO:0060544 9.65 CASP8 CFLAR
19 replicative senescence GO:0090399 9.65 CDKN2A TP53
20 cellular response to hypoxia GO:0071456 9.65 BCL2 CFLAR PTEN TP53 VEGFA
21 regulation of mitochondrial membrane permeability GO:0046902 9.64 BCL2 TP53
22 positive regulation of catenin import into nucleus GO:0035413 9.64 EGF EGFR
23 negative regulation of organ growth GO:0046621 9.63 PTEN PTK2
24 macrophage differentiation GO:0030225 9.61 CASP8 MMP9 VEGFA
25 central nervous system neuron axonogenesis GO:0021955 9.58 PTEN PTK2
26 positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process GO:2000060 9.58 EGF PTEN PTK2
27 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 9.54 CASP8 TNFRSF10B TNFSF10
28 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.46 CASP8 CFLAR TNFRSF10B TNFSF10
29 negative regulation of apoptotic process GO:0043066 9.28 BCL2 CFLAR EGFR MGMT MMP9 PTEN
30 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.26 CASP8 CFLAR TNFRSF10B TNFSF10
31 positive regulation of cell proliferation GO:0008284 10.03 BCL2 EGF EGFR PTEN PTK2 VEGFA

Molecular functions related to Malignant Glioma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.63 CDKN2A EGFR PPME1 PTEN PTK2 TP53
2 protein phosphatase 2A binding GO:0051721 9.43 BCL2 PPME1 TP53
3 protein phosphatase binding GO:0019903 9.26 BCL2 EGFR PPME1 TP53
4 identical protein binding GO:0042802 9.23 BCL2 CASP8 EGFR GFAP MMP9 PTEN
5 protein binding GO:0005515 10.25 BCL2 CASP8 CDKN2A CFLAR DMBT1 EGF

Sources for Malignant Glioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....